FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
Trial details
- Registry ID
- NCT07446322
- Drugs studied
- Bevacizumab, FOLFIRI, Pelareorep
TrialRedline tracks 2 clinical trials sponsored by Oncolytics Biotech: 2 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal CancerNCT07446322 | Bevacizumab, FOLFIRI, Pelareorep | Recruiting | 2027-08-30Estimated |
| A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 StudyNCT04215146 | Avelumab, Paclitaxel, Pelareorep | Active not recruiting | 2022-08-01Actual |
Names as written in the registry records.
Before: Not yet recruiting. After: Recruiting.